Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: RLAY relaytx.com
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company focused on developing therapies for patients with cancer and genetic disease. The company's proprietary Dynamo® platform integrates computational and experimental approaches to drug protein targets that have previously been intractable or inadequately addressed. Its lead clinical asset, zovegalisib, is a pan-mutant selective PI3Kα inhibitor currently in a Phase 3 clinical trial (ReDiscover-2) for HR+/HER2- metastatic breast cancer and is also being investigated in PI3Kα-driven vascular anomalies. The pipeline additionally includes RLY-8161 for NRAS-driven solid tumors and a program for Fabry disease. Revenue is currently derived from a license agreement with Elevar Therapeutics. The company addresses large patient populations, including approximately 140,000 patients with PI3Kα-mutated HR+/HER2- breast cancer and an estimated 170,000 patients with PI3Kα mutation-driven vascular anomalies per year in the United States. Updated
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA…
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company focused on developing therapies for patients with cancer and genetic disease.
The Wall Street consensus 12-month price target for RLAY is $27.58.
